T-CELL LYMPHOMAS
Clinical trials for T-CELL LYMPHOMAS explained in plain language.
Never miss a new study
Get alerted when new T-CELL LYMPHOMAS trials appear
Sign up with your email to follow new studies for T-CELL LYMPHOMAS, keep track of the ones that matter, and come back to a personal dashboard instead of checking manually.
Genom att skicka in godkänner du våra Användarvillkor
-
New drug combo offers hope for Hard-to-Treat lymphomas
Disease control Recruiting nowThis early-stage study tests the safety of combining two drugs, ruxolitinib and duvelisib, in people with T- or NK-cell lymphoma that has come back or not responded to prior treatments. The goal is to find the best dose and see if the combination can control the disease. About 70…
Matched conditions: T-CELL LYMPHOMAS
Phase: PHASE1 • Sponsor: Memorial Sloan Kettering Cancer Center • Aim: Disease control
Last updated May 26, 2026 12:07 UTC
-
New drug cocktail aims to outsmart tough lymphoma
Disease control Recruiting nowThis study tests a new combination of two drugs, GW5282 and golidocitinib, for people with T-cell lymphoma. The first part finds the safest dose, and the second part compares the combo to standard chemotherapy. About 165 adults with this rare blood cancer will take part.
Matched conditions: T-CELL LYMPHOMAS
Phase: PHASE1, PHASE2 • Sponsor: Dizal Pharmaceuticals • Aim: Disease control
Last updated May 26, 2026 12:06 UTC